Reynolds Holding is a Breakingviews editor who also writes from New York about the law. Before joining Breakingviews, he was a national editorial producer for the Law & Justice Unit at ABC News, a senior writer for Time magazine and the executive editor of Legal Affairs, the first general interest magazine about the law. He spent more than a decade as an investigative reporter and columnist for The San Francisco Chronicle, where he was named a Pulitzer Prize finalist for explanatory writing. Before becoming a journalist, he practiced corporate law at the New York firm of Debevoise & Plimpton. He graduated from Harvard College and Duke University School of Law.
- Tel: +1 646 223 8420
- E-mail: email@example.com
The pharmaceuticals company and hedge fund boss Bill Ackman built their Allergan stake by deftly tiptoeing around disclosure and insider trading rules. But a poison pill, antitrust issues and other pitfalls remain for the many law firms in the deal to navigate.
America’s high-tech epicenter thrives on shared ideas and expertise. The smartphone rivals stifle both by squabbling over patents and poached workers. Silicon Valley shows no signs of slowing down, but the behemoths’ penchant for protecting their empires could inhibit innovation.
Two cases challenge the hedge fund’s ability to work around U.S. laws that shield the country’s assets. The court is hearing one of them as it mulls another on paying debt-swap holdouts. Upcoming arguments in the first may reveal how creative collection plans fare in the second.
- Corporate speech ruling deaf to investor concerns
- Arbitration arbitrage whipsaws investors
- GM could use a tip from BP on contrition's risks
- Boards' defender-in-chief keeps fighting last war
- Activists crash dealmaker party
- New top U.S. M&A judge brings calm after Strine
- Company religion case may shake shareholder faith